无对比剂MRI定量参数早期预测乳腺癌新辅助化疗病理反应
研究评估乳腺癌新辅助化疗(NAC)后合成弛豫测量参数的早期变化,并建立无对比剂定量参数模型早期预测病理反应。主要队列在NAC前(n=102)、第一周期后(n=93)和第二周期后(n=90)行乳腺MRI,外部验证队列35例。主要组织学反应者(Miller-Payne G4-5)的合成弛豫参数下降程度大于非主要组织学反应者(G1-3);联合治疗后ADC、T1变化、肿瘤大小和癌症亚型的模型在第一周期后AUC为主队列0.83/验证队列0.82,第二周期后为0.85/0.84。
要点
- 主要组织学反应者(Miller-Payne G4-5)的合成弛豫参数下降程度大于非主要组织学反应者(G1-3)。
- 联合治疗后ADC、T1变化、肿瘤大小和癌症亚型的无对比剂模型第一周期后AUC为主队列0.83、验证队列0.82。
- 不同周期及大小测量序列的模型间AUC(p≥0.27)、NRI(p≥0.31)和IDI(p≥0.32)无差异。
核心结论
- 合成弛豫测量的早期下降提示NAC病理反应;无对比剂T1和ADC联合肿瘤大小及癌症亚型可在第一周期NAC后有效预测病理反应。
研究设计与样本
- 前瞻性主要队列(2019年3月至2021年1月)于NAC前(n=102)、第一周期后(n=93)和第二周期后(n=90)行乳腺MRI;外部验证队列35例(2021年2月至6月);采用多变量逻辑回归建立预测模型,以判别力、校准和临床决策曲线评估,并用DeLong检验、净重分类改善(NRI)和综合判别改善指数(IDI)比较模型。
关键影像表现/征象
- 主要组织学反应者(Miller-Payne G4-5)的合成弛豫测量参数下降程度大于非主要组织学反应者(Miller-Payne G1-3)。
- 早期治疗后所有参数均发生变化。
诊断标准与关键数值
- 联合治疗后ADC、T1变化、肿瘤大小和癌症亚型的模型第一周期后AUC为主队列0.83、验证队列0.82。
- 同一联合模型第二周期后AUC为主队列0.85、验证队列0.84。
- 不同周期及大小测量序列的模型间AUC无差异(p≥0.27)、NRI无差异(p≥0.31)、IDI无差异(p≥0.32)。
- 模型校准和决策曲线分别显示良好拟合和临床获益。
临床应用与阅片要点
- 无对比剂T1弛豫时间和ADC联合肿瘤大小及癌症亚型可用于早期预测乳腺癌NAC病理反应。
- 合成MRI弛豫测量在早期NAC后的变化可提示肿块型乳腺癌的病理反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess early changes in synthetic relaxometry after neoadjuvant chemotherapy (NAC) for breast cancer and establish a model with contrast-free quantitative parameters for early prediction of pathological response.
METHODS: From March 2019 to January 2021, breast MRI were performed for a primary cohort of women with breast cancer before (n = 102) and after the first (n = 93) and second (n = 90) cycle of NAC. Tumor size, synthetic relaxometry (T1/T2 relaxation time [T1/T2], proton density), and ADC were obtained, and the changes after treatment were calculated. Prediction models were established by multivariate logistic regression; evaluated with discrimination, calibration, and clinical application; and compared with Delong tests, net reclassification (NRI), and integrated discrimination index (IDI). External validation was performed from February to June 2021 with an independent cohort of 35 patients.
RESULTS: In the primary cohort, all parameters changed after early treatment. Synthetic relaxometry decreased to a greater degree in major histologic responders (MHR, Miller-Payne G4-5) compared with non-MHR (Miller-Payne G1-3). A model combining ADC after treatment, changes in T1 and tumor size, and cancer subtype achieved the highest AUC after the first (primary/validation cohort, 0.83/0.82) and second cycles (primary/validation cohort, 0.85/0.84). No difference of AUC (p ≥ 0.27), NRI (p ≥ 0.31), and IDI (p ≥ 0.32) was found between models with different cycles and size-measured sequences. Model calibration and decision curves demonstrated a good fitness and clinical benefit, respectively.
CONCLUSIONS: Early reduction in synthetic relaxometry indicated pathological response to NAC. Contrast-free T1 and ADC combined with size and cancer subtype predicted effectively pathological response after one NAC cycle.
KEY POINTS: • Synthetic MRI relaxometry changed after early neoadjuvant chemotherapy, which demonstrated pathological response for mass-like breast cancers. • Contrast-free quantitative parameters including T1 relaxation time and apparent diffusion coefficient, combined with tumor size and cancer subtype, stratified major histologic responders. • A contrast-free model predicted an early pathological response after the first treatment cycle of neoadjuvant chemotherapy.
引用
- Du, Gao, Zhao, et al. Contrast-free MRI quantitative parameters for early prediction of pathological response to neoadjuvant chemotherapy in breast cancer. Eur Radiol. 2022. PMID: 35267091. doi:10.1007/s00330-022-08667-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。